CEL-SCI (NYSE:CVM) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of CEL-SCI (NYSE:CVM) in a research note issued to investors on Thursday. The brokerage issued a sell rating on the stock.

CEL-SCI Trading Up 0.7 %

Shares of CEL-SCI stock opened at $0.30 on Thursday. The firm has a 50-day moving average of $0.38 and a 200-day moving average of $0.68. The stock has a market cap of $23.47 million, a PE ratio of -0.63 and a beta of 0.67. CEL-SCI has a 52-week low of $0.29 and a 52-week high of $2.39. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.09 and a current ratio of 1.07.

Institutional Investors Weigh In On CEL-SCI

A number of large investors have recently bought and sold shares of the company. Thoroughbred Financial Services LLC grew its stake in CEL-SCI by 40.1% during the fourth quarter. Thoroughbred Financial Services LLC now owns 191,661 shares of the company’s stock worth $76,000 after buying an additional 54,900 shares in the last quarter. Geode Capital Management LLC grew its stake in CEL-SCI by 9.6% during the third quarter. Geode Capital Management LLC now owns 612,861 shares of the company’s stock worth $650,000 after buying an additional 53,879 shares in the last quarter. Finally, Plotkin Financial Advisors LLC acquired a new stake in CEL-SCI during the third quarter worth about $98,000. 12.08% of the stock is currently owned by institutional investors and hedge funds.

About CEL-SCI

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.